Therrien, Amelie http://orcid.org/0000-0002-6911-8598
Silvester, Jocelyn A.
Leonard, Maureen M.
Leffler, Daniel A.
Fasano, Alessio
Kelly, Ciaran P.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK 07760, K23 DK119584)
Fonds de Recherche du Québec - Santé (MSSS/FRQS Phase 2 Award)
Article History
Received: 9 February 2020
Accepted: 28 June 2020
First Online: 11 July 2020
Compliance with Ethical Standards
:
: Not related to the current work; Daniel Leffler is employed by Takeda Pharmaceuticals International Co. Ciaran Kelly has acted as a scientific advisor to Cour Pharmaceuticals, Glutenostics, Innovate, ImmunogenX, and Takeda Pharmaceuticals. He has received research funding from Aptalis. Alessio Fasano is a stock owner of Alba Therapeutics, has received consulting fees by AbbVie, Innovate Biopharmaceuticals and uBiome, has a speaking agreement with Mead Johnson Nutritional and research agreement with Takeda. Maureen Leonard has received speaker fees from Takeda Pharmaceuticals, research funding from Glutenostics LLC and has received consulting fees from Healthmode and Anokion. Jocelyn A. Silvester has received consulting fees from Takeda Pharmaceuticals International Co, and research funding from Cour Pharmaceuticals, Biomedal SL, and Glutenostics LLC.